Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke

Neurology

Volumn 66, Issue 10, 2006, Pages 1550-1555

  Ning, M ^a   Furie, K L ^a   Koroshetz, W J ^a   Lee, H ^a   Barron, M ^a   Lederer, M ^a   Wang, X ^a   Zhu, M ^a   Sorensen, A G ^a   Lo, E H ^a   Kelly, P J ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; GELATINASE B; GELATINASE INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE PLASMINOGEN ACTIVATOR; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; BLOOD SAMPLING; BRAIN HEMORRHAGE; BRAIN SIZE; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG SAFETY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RANKIN SCALE; TREATMENT OUTCOME; ZYMOGRAPHY; BLEEDING DISORDER; BLOOD; BRAIN; BRAIN ISCHEMIA; CASE CONTROL STUDY; CHEMICALLY INDUCED DISORDER; CHRONIC BRAIN DISEASE; COMPARATIVE STUDY; CONVALESCENCE; DRUG EFFECT; ECHO PLANAR IMAGING; ENZYME INDUCTION; ENZYMOLOGY; FIBRINOLYTIC THERAPY; FOLLOW UP; HOSPITALIZATION; LEUKOCYTE COUNT; MIDDLE AGED; PATHOLOGY; TIME;

AGED; BIOLOGICAL MARKERS; BRAIN; BRAIN DAMAGE, CHRONIC; BRAIN ISCHEMIA; CASE-CONTROL STUDIES; CONVALESCENCE; ECHO-PLANAR IMAGING; ENZYME INDUCTION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HEMORRHAGIC DISORDERS; HUMANS; LEUKOCYTE COUNT; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 33745427397     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000216133.98416.b4     Document Type: Article

References (36)

1. National Institute of Neurological Disorders and Stroke tPA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587.
2. ATLANTIS, ECASS, and NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS tPA stroke trials. Lancet 2004;363:768-774.
3. Heo JH, Lucero J, Abumiya T, Koziol JA, Copeland BR, del Zoppo GJ. Matrix metalloproteinases increase very early during experimental focal ischemia. J Cereb Blood Flow Metab 1999;19:624-633.
4. Rosenberg GA, Navratil M, Barone F, Feuerstein G. Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. J Cereb Blood Flow Metab 1996;16:360-366.
5. Fukada S, Fini CA, Mabuchi T, Koziol JA, Eggleston LL, del Zoppo GJ. Focal cerebral ischemia induces active proteases that degrade microvascular matrix. Stroke 2004;35:998-1004.
6. Pfefferkorn T, Rosenberg GA. Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion. Stroke 2003;34:2025-2030.
7. Lapchak PA, Chapman DF, Zivin JA. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke 2000;31:3034-3040.
8. Asahi M, Asahi K, Jung JC, del Zoppo GJ, Fini ME, Lo EH. Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. J Cereb Blood Flow Metab 2000;20:1681-1689.
9. Wang X, Jung J, Asahi M, et al. Effects of matrix metalloproteinase-9 gene knock-out on morphological and motor outcomes after traumatic brain injury. J Neurosci 2000;20:7037-7042.
10. Tsirka SE, Gualandris A, Amaral DG, Strickland S. Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature 1995;377:340-344.
11. Nicole O, Docagne F, Ali C, et al. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med 2001;7:59-64.
12. Nassar T, Akkawi S, Shina A, et al. In vitro and in vivo effects of tPA and PAI-1 on blood vessel tone. Blood 2004;103:897-902.
13. Lo EH, Dalkara T, Moskowitz MA. Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 2003;4:399-415.
14. Wang X, Tsuji K, Lee S, et al. Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke 2004;35:2726-2730.
15. Lo EH, Broderick JP, Moskowitz MA. tPA and proteolysis in the neurovascular unit. Stroke 2004;35:354-356.
16. Aoki T, Sumii T, Mori T, Wang X, Lo EH. Blood-brain barrier disruption and matrix metalloproteinase-9 expression during reperfusion injury: mechanical versus embolic focal ischemia in spontaneously hypertensive rats. Stroke 2002;33:2711-2717.
17. Zhao B, Ikeda Y, Ihara H, et al. Essential role of endogenous tissue plasminogen activator through matrix metalloproteinase 9 induction and expression on heparin-produced cerebral hemorrhage after cerebral ischemia in mice. Blood 2004;103:2610-2616.
18. Sumii T, Lo EH. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke 2002;33:831-836.
19. Wang X, Lee S, Arai K, et al. Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med 2003;9:1313-1317.
20. Yepes M, Sandkvist M, Moore EG, Bugge TH, Strickland DK, Lawrence DA. Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest 2003; 112:1533-1540.
21. Montaner J, Molina CA, Monasterio J, et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003;107:598-603.
22. Montaner J, Alvarez-Sabín J, Molina CA, et al. Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke 2001;32:2762-2767.
23. Castellanos M, Leira R, Serena J, et al. Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke 2003;34:40-46.
24. Montaner J, Alvarez-Sabín J, Molina C, et al. Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke 2001;32:1759-1766.
25. Heo JH, Kim SH, Lee KY, Kim EH, Chu CK, Nam JM. Increase in plasma matrix metalloproteinase-9 in acute stroke patients with thrombolysis failure. Stroke 2003;34:48-50.
26. Horstmann S, Kalb P, Koziol J, Gardner H, Wagner S. Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies. Stroke 2003;34:2165-2170.
27. Castellanos M, Leira R, Serena J, et al. Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke. Stroke 2004;35:1671-1676.
28. Wang X, Mori T, Jung J-C, Fini ME, Lo EH. Secretion of matrix metalloproteinase-2 and -9 after mechanical trauma injury in rat cortical cultures and involvement of MAP kinase. J Neurotrauma 2002;19:615-625.
29. Berger C, Fiorelli M, Steiner T, et al. Hemorrhagic transformation of ischemic brain tissue: asymptomatic or symptomatic? Stroke 2001;32:1330-1335.
30. Tayebjee MH, Nadar S, Blann AD, Beevers G, MacFadyen RJ, Lip GY. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial. Am J Hypertens 2004;17:764-769.
31. Justicia C, Panes J, Sole S, et al. Neutrophil infiltration increases matrix metalloproteinase-9 in the ischemic brain after occlusion/reperfusion of the middle cerebral artery in rats. J Cereb Blood Flow Metab 2003;23:1430-1440.
32. Opdenakker G, Van den Steen PE, Dubois B, et al. Gelatinase B functions as regulator and effector in leukocyte biology. J Leukoc Biol 2001; 69:851-859.
33. Maier CM, Hsieh L, Yu F, Bracci P, Chan PH. Matrix metalloproteinase-9 and myeloperoxidase expression: quantitative analysis by antigen immunohistochemistry in a model of transient focal cerebral ischemia. Stroke 2004;35:1169-1174.
34. Rosenberg GA, Estrada EY, Dencoff JE. Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke 1998;29:2189-2195.
35. Lorenzl S, De Pasquale G, Segal AZ, Beal MF. Dysregulation of the levels of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the early stages of cerebral ischemia. Stroke 2003;34:37-38.
36. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure, and function. Biochim Biophys Acta 2000;1477:267-283.